

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 July 2025 (03.07.2025)



(10) International Publication Number
WO 2025/144899 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/535 (2006.01)
C07D 207/02 (2006.01) A61K 31/33 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/061918

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

26 December 2024 (26.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2023-0191648 26 December 2023 (26.12.2023) KR
10-2024-0003091 08 January 2024 (08.01.2024) KR

(71) Applicants: **LG CHEM, LTD.** [KR/KR]; 128, Yeouidaero, Yeongdeungpo-gu, Seoul, 07336 (KR). **RHYTHM PHARMACEUTICALS, INC.** [US/US]; 222 Berkeley Street, 12th Floor, Boston, MA 02116 (US).

(72) Inventors; and

(71) Applicants: **PARK, Hee, Dong** [KR/KR]; C/o Lg Chem, Ltd., 128, Yeouidaero, Yeongdeungpo-gu, Seoul, 07336 (KR). **HWANG, Hye, Kyeong** [KR/KR]; C/o Lg Chem, Ltd., 128, Yeouidaero, Yeongdeungpo-gu, Seoul, 07336 (KR).

(74) Agent: **LARKIN, Angelyn**; Lando & Anastasi, LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: USE OF MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF A LEPR AND/OR SH2B1 DEFICIENCY

(57) Abstract: The present disclosure relates to the use of a compound of chemical Formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing, improving, or treating a genetic obesity disease associated with the melanocortin-4 receptor (MC4R) pathway, particularly a genetic obesity disease associated with SH2B1 deficiency or a LEPR deficiency.

WO 2025/144899 A1